Biogen Seeks FDA Nod For Oral BG-12 To Treat Multiple Sclerosis - Quick Facts

FDA Approves Biogen Idec's Hemophilia B Drug Alprolix

Biogen Idec's Alprolix Gets Health Canada Approval For Hemophilia B

Eisai, Biogen Idec To Work On Two Clinical Candidates For Alzheimer's Disease

Biogen To Present At Cowen & Co. Conference; Webcast At 1:30 PM ET

Trade BIIB now with

2/28/2012 8:13 AM ET

Biogen Idec (BIIB: Quote) said it has submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, for marketing approval of BG-12 (dimethyl fumarate), the company's oral therapeutic candidate for the treatment of multiple sclerosis, or MS.

The company stated that the regulatory submission was based on BG-12's comprehensive development program, in which BG-12 demonstrated significant reductions in MS disease activity coupled with favorable safety and tolerability in the Phase 3 DEFINE and CONFIRM studies.

Biogen noted that it intends to submit a Marketing Authorisation Application for BG-12 to the European Medicines Agency within the coming days.

Click here to receive FREE breaking news email alerts for Biogen Idec and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 43 Articles

Editors Pick

Stocks May Show A Lack Of Direction In Early Trading - U.S. Commentary

After turning in a strong performance last week, stocks may show a lack of direction in early trading on Monday. The major index futures are currently pointing to a roughly flat open for the markets, with the Dow futures down by just 1 point.

Kimberly-Clark Q1 Profit Rises, Adj. EPS Tops View; Backs 2014 Adj. EPS Outlook

Healthcare products maker Kimberly-Clark Corp. (KMB) said that its first-quarter net income attributable to the company rose to $538 million from the prior year's $531 million, with earnings per share improving to $1.41 from $1.36 last year. Adjusted earnings for the quarter were $1.48 per share,...

AMD Posts Narrower Loss

Chipmaker Advanced Micro Devices Inc. said Thursday after the markets closed that its first quarter loss narrowed from last year, helped by strong revenue growth in its graphics and visual solutions business. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue.